Number of the records: 1  

TRAIL receptor upregulation and the implication of KRAS/BRAF mutations in human colon cancer tumours

  1. 1.
    SYSNO ASEP0334035
    Document TypeJ - Journal Article
    R&D Document TypeJournal Article
    Subsidiary JČlánek ve WOS
    TitleTRAIL receptor upregulation and the implication of KRAS/BRAF mutations in human colon cancer tumours
    Author(s) Oikonomou, E. (GR)
    Kosmidou, V. (GR)
    Katseli, A. (GR)
    Kothonidis, K. (GR)
    Mourtzoukou, D. (GR)
    Kontogeorgos, G. (GR)
    Anděra, Ladislav (UMG-J) RID
    Zografos, G. (GR)
    Pintzas, A. (GR)
    Number of authors9
    Source TitleInternational Journal of Cancer. - : Wiley - ISSN 0020-7136
    Roč. 125, č. 9 (2009), s. 2127-2135
    Number of pages9 s.
    Languageeng - English
    CountryDE - Germany
    Keywordscolorectal tumours ; TRAIL receptors expression ; KRAS/ BRAF oncogenic mutations
    Subject RIVEB - Genetics ; Molecular Biology
    R&D Projects1M0506 GA MŠMT - Ministry of Education, Youth and Sports (MEYS)
    CEZAV0Z50520514 - UMG-J (2005-2011)
    UT WOS000270750000016
    DOI10.1002/ijc.24613
    AnnotationTRAIL raises hopes as a promising anti-tumor agent due to its selectivity toward cancer cells. Since TRAIL receptor availability can be analogous to ligand efficacy, we performed RT-PCR and immunohistochemical analysis of DR4 and DR5 in 51 colon cancer biopsy specimens and respective normal mucosa. The results showed that DR4 and DR5 were significantly upregulated in 37 and 47% of the tumor samples respectively, while both DR4 and DR5 were co-instantaneously upregulated in 31% of the samples analyzed. Positive transcriptional regulation of DRs was recorded as early as Dukes' A stage. Possible contribution of frequent oncogenic mutations in the MAPK pathway was investigated by direct sequencing in all 51 tumors. Samples (6/8) hosting either a KRAS(G12V) or BRAF(V600E) mutation, significantly amplified the upregulated expression of DR4 and DR5, showing strong inter-relation between overexpression and presence of oncogenic KRAS/ BRAF mutations and DRs expression.
    WorkplaceInstitute of Molecular Genetics
    ContactNikol Škňouřilová, nikol.sknourilova@img.cas.cz, Tel.: 241 063 217
    Year of Publishing2010
Number of the records: 1  

  This site uses cookies to make them easier to browse. Learn more about how we use cookies.